Stephen Santoro

Title: The Innovative Journey of Stephen Santoro

Introduction

Stephen Santoro, an accomplished inventor based in Daly City, California, has made significant contributions to the field of biomedicine through his innovative patents. With a total of four patented inventions, Santoro's work primarily focuses on chimeric antigen receptors and their applications in immune therapies.

Latest Patents

Among his latest patents, one highlights the methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors. This innovation provides a thorough description of chimeric antigen receptors designed to bind specifically to B-cell maturation antigen (BCMA) and CD307e. The patent also covers the nucleic acids encoding these receptors and the methods for making and utilizing them.

Another notable patent by Santoro involves immune cells having co-expressed shRNAs and logic gate systems. This patent outlines recombinant nucleic acids that encode chimeric priming receptors that bind ALPG/P and chimeric antigen receptors that bind MSLN. It includes shRNA targeting essential genes like FAS, PTPN2, and TOX, as well as systems comprised of these receptors and shRNAs, providing a comprehensive framework for their application in cellular therapies.

Career Highlights

Stephen Santoro has worked with prestigious companies such as Cell Design Labs, Inc. and Arsenal Biosciences, Inc., where he utilized his expertise in developing advanced therapies. His relentless pursuit of innovation has paved the way for new approaches in targeting cancer cells and enhancing immune responses.

Collaborations

Throughout his career, Santoro has collaborated with notable figures in the industry, including Peter Emtage and Scott Coyle. These partnerships have fostered a dynamic exchange of ideas and have been instrumental in driving forward groundbreaking research in the field of immunotherapy.

Conclusion

Stephen Santoro's dedication to innovation and his impressive portfolio of patents underscore his role as a leading inventor in the biomedicine sector. His contributions toward the development of chimeric antigen receptors are helping to shape the future of targeted therapies, providing new hope for patients battling various diseases.